UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema

Journal of comparative effectiveness research, 2024-05, Vol.13 (5), p.e240041-e240041

2024

Volltextzugriff (PDF)

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

PharmacoEconomics, 2017-11, Vol.35 (11), p.1123-1140

2017

Volltextzugriff (PDF)

Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement

Heart (British Cardiac Society), 2012-03, Vol.98 (5), p.370-376

2012

Volltextzugriff (PDF)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

Journal of comparative effectiveness research, 2023-06, Vol.12 (6), p.e220188-e220188

2023

Volltextzugriff (PDF)

Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema

Journal of patient-reported outcomes, 2023-04, Vol.7 (1), p.33-33, Article 33

2023

Volltextzugriff (PDF)

Correction to: Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema

Journal of patient-reported outcomes, 2023-06, Vol.7 (1), p.53-53, Article 53

2023

Volltextzugriff (PDF)

Real-World Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Blood, 2019-11, Vol.134 (Supplement_1), p.2411-2411

2019

Volltextzugriff (PDF)

The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study

International journal of infectious diseases, 2015-07, Vol.36 (C), p.31-38

2015

Volltextzugriff (PDF)

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-09, Vol.28 (5), p.e117-e120

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns and Characteristics of Patients With Hereditary Angioedema Treated With Lanadelumab: Results From a US Retrospective Chart Review Study

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB75

2024

Volltextzugriff (PDF)

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

Blood, 2018-11, Vol.132 (Supplement 1), p.2484-2484

2018

Volltextzugriff (PDF)

Burden of Illness in Female and Male Adult Patients With Hereditary Angioedema: Findings From a Multinational Survey

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB93

2024

Volltextzugriff (PDF)

Burden of Illness in Adult Patients With Controlled and Poorly Controlled Hereditary Angioedema: Findings From a Multinational Survey

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB92

2024

Volltextzugriff (PDF)

Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents

Annals of allergy, asthma, & immunology, 2024-08

2024

Volltextzugriff (PDF)

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Journal of managed care & specialty pharmacy, 2020-04, Vol.26 (4), p.492-503

2020

Volltextzugriff (PDF)

A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

Infection, 2016-10, Vol.44 (5), p.599-606

2016

Volltextzugriff (PDF)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

Journal of antimicrobial chemotherapy, 2018-09, Vol.73 (9), p.2529-2539

2018

Volltextzugriff (PDF)

Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

Annals of allergy, asthma, & immunology, 2023-07, Vol.131 (1), p.101-108.e3

2023

Volltextzugriff (PDF)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland

Journal of health economics and outcomes research (Online), 2015-05, Vol.2 (2), p.192-206

2015

Volltextzugriff (PDF)

Effectiveness, Safety, and Patient-Reported Outcomes (PROs) in Patients With Hereditary Angioedema (HAE) From the United States and Canada Treated With Lanadelumab: 24-Month Data From the EMPOWER Study

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB131-AB131

2023

Volltextzugriff (PDF)

Health-Related Quality of Life (HRQoL) in Pediatric Patients with Hereditary Angioedema (HAE) Receiving Lanadelumab: Exploratory Results From the SPRING Study

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB139-AB139

2023

Volltextzugriff (PDF)

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB24-AB24

2021

Volltextzugriff (PDF)

Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada: Final Data From the EMPOWER Study

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB242

2024

Volltextzugriff (PDF)

Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France

Journal of medical economics, 2017-07, Vol.20 (7), p.678-686

2017

Volltextzugriff (PDF)

Antibiotic research and development: business as usual?

Journal of antimicrobial chemotherapy, 2015, Vol.70 (6), p.1604-1607

2015

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(75)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema

Correction to: Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema

Real-World Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study

Real-World Treatment Patterns and Characteristics of Patients With Hereditary Angioedema Treated With Lanadelumab: Results From a US Retrospective Chart Review Study

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

Burden of Illness in Female and Male Adult Patients With Hereditary Angioedema: Findings From a Multinational Survey

Burden of Illness in Adult Patients With Controlled and Poorly Controlled Hereditary Angioedema: Findings From a Multinational Survey

Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland

Effectiveness, Safety, and Patient-Reported Outcomes (PROs) in Patients With Hereditary Angioedema (HAE) From the United States and Canada Treated With Lanadelumab: 24-Month Data From the EMPOWER Study

Health-Related Quality of Life (HRQoL) in Pediatric Patients with Hereditary Angioedema (HAE) Receiving Lanadelumab: Exploratory Results From the SPRING Study

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada: Final Data From the EMPOWER Study

Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France

Antibiotic research and development: business as usual?

Suchergebnisse filtern